Early risk stratification and temporal biomarker patterns of trousseau syndrome-related cerebral infarction in lung cancer - Top-Institutions - MDSpire

Early risk stratification and temporal biomarker patterns of trousseau syndrome-related cerebral infarction in lung cancer

  • By

  • Ziyi Xiao

  • Wenbo Zhang

  • Yikai Han

  • Jiaxin Pei

  • Yushu Deng

  • Mengmeng Yang

  • Feng Wang

  • Taiying Lu

  • June 9, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    First Affiliated Hospital of Zhengzhou University
    First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan

    Key Differentiators

    • Neurology
    • Oncology

  • #2

    UK Biobank
    UK Biobank

    Manchester, England

    Key Differentiators

    • Epidemiology
    • Genetics

  • #3

    Mass General Brigham Biobank
    Mass General Brigham Biobank

    Boston, Massachusetts

    Key Differentiators

    • Biobank
    • Oncology

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Research

  • #5

    Washington University School of Medicine
    Washington University School of Medicine

    St. Louis, Missouri

    Key Differentiators

    • Medicine
    • Research

Original Source(s)

Early risk stratification and temporal biomarker patterns of trousseau syndrome-related cerebral infarction in lung cancer

  • by Ziyi Xiao, Wenbo Zhang, Yikai Han, Jiaxin Pei, Yushu Deng, Mengmeng Yang, Feng Wang, Taiying Lu

  • June 9, 2026

Related Content

Harnessing Vδ1+ T cells for next-generation immunotherapy: from mechanistic insights to clinical translation

This Week’s CGT News: Promising Data for In Vivo CAR T

Legend and Kelonia reveal 100 percent response rates in phase 1 trials, dual CAR T opens doors for kidney transplant patients, and iPDSC therapy beefs up failing hearts

  • June 8, 2026

  • 6 min
Multi-omics analysis of kidney renal cell carcinoma in silico with preliminary in vivo validation